Equities Analysts Set Expectations for Genelux Q1 Earnings

Genelux Co. (NASDAQ:GNLX) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for Genelux in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.16) per share for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.22) EPS and FY2029 earnings at $2.58 EPS.

Genelux Stock Performance

NASDAQ GNLX opened at $3.03 on Wednesday. The stock has a market cap of $104.65 million, a PE ratio of -3.19 and a beta of -1.41. The firm has a 50-day moving average of $4.05 and a 200-day moving average of $3.09. Genelux has a 52-week low of $1.60 and a 52-week high of $6.50.

Institutional Investors Weigh In On Genelux

A number of institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in Genelux during the 4th quarter worth approximately $25,000. Apollon Wealth Management LLC increased its position in Genelux by 20.4% during the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after buying an additional 2,857 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Genelux during the fourth quarter worth $41,000. Brown Brothers Harriman & Co. boosted its position in shares of Genelux by 76.2% in the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock valued at $50,000 after acquiring an additional 9,114 shares during the period. Finally, D.A. Davidson & CO. acquired a new position in shares of Genelux in the fourth quarter valued at about $51,000. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.